PCI Biotech Holding ASA (OSL:PCIB) EPS (Basic) : kr-0.44 (TTM As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA EPS (Basic)?

PCI Biotech Holding ASA's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was kr-0.24. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.44.

PCI Biotech Holding ASA's EPS (Diluted) for the six months ended in Dec. 2024 was kr-0.24. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.44.

PCI Biotech Holding ASA's EPS without NRI for the six months ended in Dec. 2024 was kr-0.24. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.44.

During the past 3 years, the average EPS without NRI Growth Rate was 43.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 30.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, PCI Biotech Holding ASA's highest 3-Year average EPS without NRI Growth Rate was 43.00% per year. The lowest was -44.50% per year. And the median was -0.25% per year.

PCI Biotech Holding ASA EPS (Basic) Historical Data

The historical data trend for PCI Biotech Holding ASA's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA EPS (Basic) Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-1.94

-2.37

-1.48

-0.54

-0.44

PCI Biotech Holding ASA Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.47	-0.32	-0.23	-0.20	-0.24

PCI Biotech Holding ASA EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

PCI Biotech Holding ASA's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-16.417	-	0)	/	37.311
	=	-0.44

PCI Biotech Holding ASA's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-9.015	-	0)	/	37.563
	=	-0.24

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.44

PCI Biotech Holding ASA (OSL:PCIB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

PCI Biotech Holding ASA EPS (Basic) Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

0JGL:UK 4QG:Germany

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines